HomeContact Site map   Google    www    iipm think tank
   
   
Home Scrutiny Publications Under Cover Mus'ings  
 

Home > Scrutiny > We don’t make clones! We do?!?!

  
   
     
   Case Studies  
       
  Marketing    
  Human Resource    
  Information Technology    
  Finance    
  Strategy    
       
 
     
   Industries  
       
  Steel    
  Glass    
  Banking    
  Prophylactic    
  Auto    
  Hospitality    
  Energy    
       
 
     
   Other links  
       
  IIPM    
  Planman Consulting    
  Planman Marcom    
  Planman Technologies    
  Daily Indian Media    
  Planman Financial    
  4P's Business and Marketing    
  Business and Economy    
  The Daily Indian    
  The Sunday Indian    
  Arindam Chaudhuri    
  GIDF    
       
 
  
         
Scrutiny
  
We don’t make clones! We do?!?!
That was just a joke... But drug testing is getting big in India; serious!!!
27/11/2008

India has made a mark in the low-end bio-equivalence testing for generic drugs. With its huge patient base, low cost advantage, completion of clinical test on time, improving infrastructure, the platform is experiencing a double-digit growth in the clinical trials market. All major pharmaceutical companies and Clinical Research Organisations (CROs) have started conducting their clinical tests in India, and with improving infrastructure, industry friendly regulations and trained workforce, the growth is only likely to increase in the near future. Statistics also show that during the last three years, the industry turnover has increased from Rs.200 million crores to Rs.1 billion. According to a 2008 McKinsey report, the industry is expected to touch the dream figure of Rs.50 billion by 2010.

But there are challenges too! To achieve its goal of becoming a global hub of clinical trials, the country will have to conquer roadblocks like unethical trials, delay in trial approval (India takes 6-8 months for forming a ‘Phase-I molecule investigational new drug’ committee. This is in sharp contrast to 28 days in Canada, Europe, UK and many other countries), inappropriate protection of clinical data, and lack of Good Clinical Practice (GCP) certified sites and investigators. Bio-analytical work is also another profitable technological process where Indian skill base is low. There is a need of bio-analytical scientists in order to fill this need.

Global drug companies are seeking a suitable destination within the country to conduct clinical research as India has the second largest pool of qualified doctors, next only to US. [Even in US, one out of every six doctors is an Indian.]Moreover, these companies want to exploit the cost advantage for all the margin expenses associated with clinical trials and patient monitoring such as CT scans, blood tests, X-rays and other similar basic medical tests which are cheaper in India as compared to US and Europe.

By:- B&E
Back

  
 
 
       
Home | Scrutiny | Publications | About us | Contact us
Copyright @2010 iipm think tank. All rights reserved.